SCNX Scienture Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1382574 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY127.4%
TTM net income YoY-96.3%
TTM EPS YoY144.2%
Revenue 3-yr CAGR-24.9%
Net income 3-yr CAGR—
Margins
Gross margin78.5%
Operating margin-2,788.5%
Net margin-2,715.9%
FCF margin—
EBITDA margin-2,662.9%
Returns
ROE-57.1%
ROA-47.1%
ROIC (approx.)-47.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets32.6%
Debt / equity0.00x
Current ratio1.10x
Interest coverage-25.26x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $431,609 | $136,643 | $1.36M | $10.25M | $9.89M |
| Cost of revenue | $100,127 | $130,638 | $1.31M | $4.73M | $5.14M |
| Gross profit | $331,482 | $6,005 | $49,030 | $5.52M | $4.75M |
| R&D expense | $1.96M | $2.24M | — | — | — |
| SG&A expense | $7.93M | $6.68M | $1.34M | $1.69M | $1.90M |
| Operating income | -$42.59M | -$14.70M | -$4.40M | -$2.92M | -$5.29M |
| Interest expense | $4.08M | $1.34M | $1.14M | $336,206 | $23,590 |
| Pretax income | -$43.51M | -$18.78M | -$8.48M | — | — |
| Income tax | -$1.99M | -$534,396 | — | — | — |
| Net income | -$41.51M | $9.07M | -$17.84M | -$3.47M | -$5.32M |
| EBITDA | -$42.10M | -$14.70M | -$4.38M | -$2.90M | -$5.28M |
| EPS (basic) | -2.70 | 2.69 | -23.35 | -6.15 | -0.65 |
| EPS (diluted) | -2.70 | 2.48 | -23.35 | -6.13 | -0.65 |
| Weighted avg. shares (diluted) | 15.35M | 3.65M | 2.38M | 566,609 | 8.14M |
| Banking | |||||
| Deposits | $1.18M | — | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $6.66M | $308,096 | $314 | $1.09M | $3.12M |
| Receivables | $731,328 | $11,106 | $8,492 | $629,921 | $978,973 |
| Inventory | $213,408 | — | $968 | $65,523 | $56,279 |
| Current assets | $7.92M | $6.31M | $2.75M | $2.09M | $4.37M |
| PP&E, net | $15,500 | $17,500 | $7,500 | $65,214 | $98,751 |
| Goodwill | — | $21.37M | — | $0 | $0 |
| Intangibles | $70.97M | $76.40M | $8.96M | — | — |
| Total assets | $84.18M | $104.85M | $12.53M | $3.71M | $5.77M |
| Current liabilities | $2.74M | $7.91M | $11.56M | $2.15M | $926,026 |
| Long-term debt | — | $2.90M | — | — | — |
| Total debt | — | $2.90M | — | — | — |
| Total liabilities | $14.06M | $25.78M | $11.99M | $3.37M | $2.00M |
| Shareholders' equity | $70.12M | $79.07M | $542,353 | $763,136 | $3.77M |
| Net debt | — | $2.59M | — | — | — |
| Shares outstanding | 1.63M | 8.75M | 905,008 | 626,247 | 8.17M |
| Cash flow statement | |||||
| Operating cash flow | -$13.38M | -$14.27M | -$2.23M | -$199,020 | -$2.57M |
| Capital expenditure | — | $12,000 | — | — | $22,596 |
| Free cash flow | — | -$14.28M | — | — | -$2.59M |
| Investing cash flow | — | $27.55M | -$275,717 | $749 | -$22,596 |
| Financing cash flow | $19.73M | -$12.98M | $1.41M | $239,829 | -$208,178 |
| Depreciation & amortization | $491,781 | $2,000 | $19,375 | $13,486 | $7,351 |
| Stock-based compensation | $2.07M | $25,584 | $29,738 | $79,163 | $64,167 |
| Dividends paid | — | $14.86M | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.